Response of metastatic breast cancer to trastuzumab?

Lancet. 2000 Jan 15;355(9199):160-1. doi: 10.1016/S0140-6736(99)00430-4.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Female
  • Humans
  • Receptor, ErbB-2 / metabolism
  • Trastuzumab
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab